This activity is intended for hematologists/oncologists (community and academic), PAs, NPs, and other members of the interprofessional, multidisciplinary cancer care team on a global level that interface with patients with NHL.

After completing this CE activity, the participant should be better able to:

• • Assess the expanding treatment landscape for patients with NHL, including new and emerging non-CART options such as bispecific antibodies, and its impact on individualized treatment selection and treatment sequencing.
  • Analyze available CAR T-cell therapies for patients with relapsed/refractory NHL based on the latest safety and efficacy trial data and currently approved indications.
  • Conduct comprehensive evaluation to determine eligibility and potential benefits of CAR T-cell therapy based on recent clinical trial data, guideline recommendations, as well as patient-, disease-, and treatment-specific factors.
  • Identify suitable candidates that might benefit from CAR T-cell therapy in an outpatient setting versus an inpatient setting to support patient preference and satisfaction.
  • Apply a multidisciplinary approach to coordinate care between referring physician, establishing outpatient CART centers, and cross-collaboration with clinical teams to ensure individualized and optimal patient management. 

In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

This activity is provided by MLI

Physician Continuing Medical Education

Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

ECMEC^(R) Credit

The European Union of Medical Specialists-European Accreditation Council for Continuing Medical Education (UEMS-EACCME^â) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit(s)^TM into European CME credit (ECMEC^â) should contact the UEMS (www.uems.eu).

Physician Associate  

Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.65 contact hour in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

All disclosures will be provided to learners prior to the live presentation on Friday, May 31, 2024.